Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib 70 mg in newly diagnosed CML-CP
NCT04155411Phase 4Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Major Molecular Response at 12 months. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04155411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155411.